Drug development in patients with advanced non-small cell lung cancer and poor performance status

Seminars in Oncology

Volumn 31, Issue SUPPL. 11, 2004, Pages 21-26

  Stinchcombe, Thomas E ^a,b   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Multidisciplinary Thoracic Oncology Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ANEMIA; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GENETIC HETEROGENEITY; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PERFORMANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 10044293225     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.10.005     Document Type: Article

References (26)

1. R. Stephens The Big Lung Trial: Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC): Preliminary results in the supportive care setting Proc Am Soc Clin Oncol 21 2002 291a (abstr 1161)
2. M.H. Cullen, L.J. Billingham, C.M. Woodroffe Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer Effects on survival and quality of life J Clin Oncol 17 1999 3188 3194
3. H. Anderson, R. Hopwood, R. Stephens Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--A randomized trial with quality of life as the primary outcome Br J Cancer 83 2000 447 453
4. K. Kelly Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status Semin Oncol 31 suppl 11 2004 3 7
5. D.G. Pfister, D.H. Johnson, C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guidelines Update 2003 J Clin Oncol 22 2004 330 353
6. J.C. Ruckdeschel, D.M. Finkelstein, D.S. Ettinger A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer J Clin Oncol 4 1986 14 22
7. C.J. Sweeney, J. Zhu, A.B. Sandler Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 A phase II trial in patients with metastatic nonsmall cell lung carcinoma Cancer 92 2001 2639 2647
8. R. Lilenbaum Management of advanced non-small-cell lung cancer in patients with a performance status of 2 Clin Lung Cancer 5 2004 209 213
9. C.C. Earle, P.J. Neumann, R.D. Gelber Impact of referral patterns on the use of chemotherapy for lung cancer J Clin Oncol 20 2002 1786 1792
10. L.J. Billingham, M.H. Cullen The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer Ann Oncol 12 2001 1671 1675
11. C. Langer, P. Stephenson, J. Schiller ECOG 1599 Randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC Lung Cancer 41 suppl 2 2003 S18
12. W.J. Tester, P. Stephenson, C.J. Langer ECOG 1599 Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 627 (abstr 7055)
13. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
14. F.A. Shepherd, J. Pereira, T.E. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st or 2nd line chemotherapy A National Institute of Canada Clinical Trials Group (NCIC CTG) trial Proc Am Soc Clin Oncol Late-Breaking Abstracts Booklet 23 2004 18 (abstr 7022)
15. M.D. Miller, C.F. Paradis, P.R. Houck Rating chronic medical illness burden in geropsychiatric practice and research Application of the Cumulative Illness Rating Scale Psychiatry Res 41 1992 237 248
16. M. Extermann Measuring comorbidity in older cancer patients Eur J Cancer 36 2000 453 471
17. M.E. Charlson, P. Pompei, K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies Development and validation J Chronic Dis 40 1987 373 383
18. S. Firat, R.W. Byhardt, E. Gore Radiation Therapy Oncology Group Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer An institutional analysis of patients treated on four RTOG studies Int J Radiat Oncol Biol Phys 54 2002 357 364
19. G. Frasci, V. Lorusso, N. Panza Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer J Clin Oncol 18 2000 2529 2536
20. J.E. Groopman, L.M. Itri Chemotherapy-induced anemia in adults Incidence and treatment J Natl Cancer Inst 91 1999 1616 1634
21. C. Langer, A. Barsevick, D. Bruner Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel Lung Cancer 18 1997 23 (abstr)
22. C. Langer, R. Lilenbaum Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer Semin Oncol 31 suppl 11 2004 8 15
23. M.S. Norton, M. Neubauer, H. Harper Phase 2 study of first line chemotherapy using CT-2103 in patients with non-small-cell lung cancer who are <70 years of age or performance status (PS) = 2 Proc Am Soc Clin Oncol 22 2003 653 (abstr 2626)
24. C. Aghajanian, S. Soignet, D. Dizon A phase I trial of the novel Proteasome Inhibitor PS341 in advanced solid tumor malignancies Proc Am Soc Clin Oncol 20 2001 85a (abstr)
25. E.S. Kim, A.M. Mauer, H.T. Tran A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer Final report Pro Am Soc Clin Oncol 22 2003 642 (abstr 2581)
26. M.P. Fanucchi, R.J. Belt, F.V. Fossella Phase (ph) II study of bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) Preliminary results Proc Am Soc Clin Oncol 23 2004 640 (abstr 7107)